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Abstract The introduction of biological agents targeting
tumor necrosis factor-alpha (TNF-a) has brought about a
paradigm shift in the treatment of rheumatoid arthritis (RA).
Although these anti-TNF agents have excellent efﬁcacy
against RA, a substantial number of patients still show inad-
equate responses. In Western countries, such patients are
alreadybeingtreatedwithnewclassesofantirheumaticdrugs
such as abatacept and rituximab. Tocilizumab (TCZ) is a
humanized monoclonal antibody developed in Japan against
the human interleukin-6 (IL-6) receptor. TCZ does not only
alleviate the signs and symptoms of RA but also seems to
prevent progressive bone and joint destruction. However,
there isa concern thatTCZ mightincrease the risk ofadverse
eventssuch as infections since IL-6 plays a pivotal rolein the
immune system. Calculating the relative risks of speciﬁc
adverse outcomes with TCZ use remains difﬁcult, due to
insufﬁcient patient numbers enrolled in clinical trials to date.
This review presents tentative guidelines for the use of TCZ
for RA patients prepared by the Japan College of Rheuma-
tology and based on results of clinical trials in Japan and
Western countries. The guidelines are intended as a guide for
postmarketing surveillance and clinical practice, and will be
revised periodically based on the surveillance.
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Introduction
The introduction of biological agents has signiﬁcantly
altered the natural course of rheumatoid arthritis (RA) and
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DOI 10.1007/s10165-009-0197-6associated joint destruction. Anti-tumor necrosis factor-
alpha (TNF-a) agents, inﬂiximab and etanercept, show
excellent efﬁcacy in Japanese RA patients. However, the
use of these anti-TNFs has been linked to potentially serious
adverse effects, particularly infections and malignancies.
The Japan College of Rheumatology (JCR) therefore
released speciﬁc guidelines developed speciﬁcally for the
proper use of these agents [1].
Tocilizumab (TCZ) is a humanized anti-human inter-
leukin-6 receptor (IL-6R) monoclonal antibody developed
recently in Japan. TCZ binds to the alpha chain of both
membrane-bound and soluble IL-6R, thus blocking IL-6/
IL-6R signaling [2, 3]. In the recent Japanese clinical
trial of TCZ monotherapy, 80.3% of patients on 8 mg/kg
TCZ achieved the American College of Rheumatology
improvement criteria 20% (ACR20) response [4]. TCZ
does not only suppress the signs and symptoms of RA but
also inhibits bone and joint destruction in RA patients [5].
In the European phase III clinical trial, 50.0% of patients
on 8 mg/kg TCZ achieved ACR20 at 24 weeks [6]. It is
reported that TCZ is effective even in RA patients refrac-
tory to anti-TNF biologics [6]. TCZ is also effective
against multicentric Castleman disease [7] and juvenile
inﬂammatory arthritis (JIA) [8], and as of January 2009,
TCZ has been approved for clinical use against RA as well
as these two conditions, but only in Japan.
Since TCZ is a drug with a new mode of action,
unexpected adverse effects may be encountered when
used in a variety of RA patients in daily practice.
Although both efﬁcacy and safety proﬁles of TCZ for
RA have been substantiated in clinical trials, the rela-
tively small patient numbers to date preclude accurate
detection and risk assessment of adverse events associ-
ated with this drug, particularly rare occurrences. Fur-
thermore, patients enrolled in clinical trials are carefully
selected based on both inclusion and exclusion criteria
and thus differ from those in daily practice in terms of
risk analysis.
The Ministry of Health, Labor, and Welfare (MHLW)
commissioned Chugai Pharmaceutical Company to under-
take a postmarketing surveillance of the initial 3,000 cases
for adverse events. Based on this, and data of clinical trials
conducted in Japan and Western countries, the JCR for-
mulated ofﬁcial guidelines for the use of TCZ in Japan [9]
(Table 1). The guidelines are equivalent to a ‘‘clinical
guide to use’’ and subject to change periodically based on
the pharmacovigilance activities in Japan. The JCR also
organized a committee for the medical treatment of rheu-
matic disease. The committee designed a proposal for the
initial guidelines on the safe use of TCZ, which were then
discussed and approved by the JCR board of directors. The
guidelines were subject to the standard journal review
process.
Eligibility and inclusion criteria for TCZ
TCZ is recommended for patients who are diagnosed by
the American College of Rheumatology 1987 classiﬁcation
criteria for the diagnosis of RA [10], and who show inad-
equate response despite treatment for at least 3 months
with the maximum permissible dose of one of the nonbi-
ologic disease-modifying antirheumatic drugs (DMARDs)
[methotrexate (MTX), bucillamine, sulfasalazine, leﬂuno-
mide, or tacrolimus] rated as ‘‘recommendation A level’’ in
the diagnostic manual and evidence-based treatment
guidelines [11] developed by the study group of the
MHLW, or tacrolimus approved as DMARD only in Japan
with some efﬁcacy data [12, 13]. Patients showing inade-
quate response to the biologic DMARDs approved in Japan
(inﬂiximab, etanercept, and adalimumab) are also included.
Inadequate response to previous treatment is deﬁned by the
presence of at least six tender joints and swollen joints, and
either C-reactive protein (CRP) levels of at least 2.0 mg/dl
or an erythrocyte sedimentation rate (ESR) of at least
28 mm/h.
To avoid potential opportunistic infections, patients
should have a peripheral leukocyte count of 4,000/mm
3 or
more, a peripheral lymphocyte count of 1,000/mm
3 or
more, and a negative test for blood b-D-glucan. These
criteria are similar to those set for the use of anti-TNF
agents in RA patients [1] and are based on the important
role played by cellular immunity against opportunistic
infections caused by Mycobacterium tuberculosis or fungi
such as Pneumocystis jiroveci, and that these infections are
likely to occur in patients with low peripheral lymphocyte
counts [14]. A test for blood b-D-glucan, a component of
fungi, has been included in the diagnosis of fungal infec-
tions, especially those with Pneumocystis jiroveci.
Exclusion criteria for TCZ
Active infection
TCZ is contraindicated in patients with ongoing infections,
as is the case for other biologics. IL-6 is the major inducer
of inﬂammatory responses against infection [15], thus TCZ
could mask signs of infection such as fever, general mal-
aise, and elevation of surrogate markers including CRP and
ESR, and consequently make early diagnosis of infections
more difﬁcult. However, symptoms such as cough, sputum,
and dyspnea are not masked with TCZ. Leukocytosis and a
left shift in neutrophil count are also not suppressed by
TCZ. Furthermore, radiographic analysis can be used to
detect early-stage respiratory infections.
As a precaution against tuberculosis, candidate patients
for treatment with TCZ must also undergo a thorough
review of family and past history of tuberculosis, chest
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123radiography, and a puriﬁed protein derivative (PPD)
skin test. Suspected abnormalities on chest radiography
should be further investigated by computed tomography
of the chest. TCZ is contraindicated in patients with
abnormalities on chest radiography such as linear opacities,
calciﬁcation larger than 5 mm, and pleural thickening
suggestive of old tuberculosis, and in individuals with
pulmonary or extrapulmonary tuberculosis. However,
Table 1 Guidelines for the use of tocilizumab (TCZ) for treatment of rheumatoid arthritis
Eligibility and inclusion criteria
1. Patients fulﬁlling the American College of Rheumatology 1987 Classiﬁcation criteria for the diagnosis of rheumatoid arthritis (RA) and
showing inadequate response to conventional treatment. Inadequate response of RA to previous treatment is deﬁned as the presence of the
following three clinical ﬁndings:
Tender joints C6
Swollen joints C6
ESR C28 mm/h or CRP C2.0 mg/dl
2. Patients showing inadequate control despite treatment for at least 3 months with standard doses of conventional biological or nonbiological
disease-modifying antirheumatic drugs (DMARDs) [e.g., methotrexate (MTX), bucillamine, leﬂunomide, tacrolimus, sulfasalazine,
biological DMARD inﬂiximab, etanercept, and adalimumab]
3. It is recommended that patients should have the following laboratory test results in order to avoid potential opportunistic infections:
WBC C4,000/mm
3
Peripheral blood lymphocytes C1,000/mm
3
Serum or plasma (1 to[3)-b-D-glucan: negative
Exclusion criteria
1. Active infection
Bacterial infection
Mycobacterial infection including latent tuberculosis deﬁned by history, puriﬁed protein derivative (PPD) skin test, radiography, or
interferon-c releasing assay
Chronic active Epstein–Barr virus (CAEBV) infection deﬁned by detection of EBV genome in peripheral blood
Active hepatitis B virus (HBV) infection
2. History of serious hypersensitivity reaction against TCZ
Dosage of TCZ
Administer 8 mg/kg diluted in 100–250 ml saline by drip infusion every 4 weeks.
When starting infusion, observe the patient carefully. In the absence of abnormal symptoms, drip infusion should be completed in about 1 h.
Cautions
There are several issues related to safety of TCZ. When starting or continuing TCZ therapy, it is necessary to notify and be prepared for the
following complications, medical interventions, and/or conditions:
1. Infection. Infectious disease, especially respiratory infection, is the most important based on its frequency and severity. When symptoms, such
as fever, cough, and dyspnea, occur under TCZ therapy, it is necessary to notify the condition and consult the diagnostic ﬂow chart shown in
Fig. 1
Bacterial pneumonia
Tuberculosis and nontuberculous mycobacterial infection
Pneumocystis pneumonia
2. Bowel perforation and secondary peritonitis. Several cases with bowel perforation followed by peritonitis have been reported.
3. Hyperlipidemia. TCZ therapy is reported to increase serum levels of lipids, cholesterol, and/or triglycerides.
4. Transient neutropenia. Neutropenia is reported in patients on TCZ therapy although the majority of cases are transient and often mild in
nature.
5. Use with other DMARDs. TCZ has been approved for use without concomitant DMARDs in Japan. When considering combining TCZ with
other DMARDs, it is necessary to evaluate the indications and to monitor the adverse events with utmost care.
6. Serious infusion reactions. Severe infusion reactions may require airway maintenance, oxygen inhalation, subcutaneous epinephrine, and
intravenous corticosteroid.
7. Surgery under TCZ therapy. Because TCZ might delay wound healing and mask surgical-site infection, surgery should be postponed until
clearance of drug from the bloodstream, i.e., for at least 14 days after the last infusion of the drug.
8. Use during pregnancy and lactation. Avoid use of TCZ in pregnant and lactating women due to concerns regarding safety for embryos and
neonates.
9. Use in patients with malignancies. Consider carefully prescription of TCZ for patients with precancerous lesions or recent history of neoplasm
because it remains unclear whether TCZ affects carcinogenesis or not.
Mod Rheumatol (2009) 19:351–357 353
123treatment with TCZ may be considered together with
antituberculosis agents only if the potential beneﬁts out-
weigh the potential risks. In patients with a strongly posi-
tive PPD skin test (presence of induration) or radiographic
opacities suggestive of old pulmonary tuberculosis, treat-
ment with isoniazid (0.3 g/day or 5 mg/kg for low-body-
weight patients) should be initiated at least 3 weeks prior to
administration of TCZ and continued for the subsequent 6–
9 months. It is advisable that patients with active nontu-
berculous mycobacterial infection are excluded from TCZ
treatment because it is often difﬁcult to control these
infections.
It remains unclear whether blocking the IL-6/IL-6R
pathway directly induces the proliferation or activation of
herpes group viruses such as Epstein–Barr virus (EBV).
However, it would be better for patients with active EBV
infection, deﬁned by detection of EBV genes in peripheral
blood, to avoid treatment with TCZ. One case died from
hemophagocytosis associated with reactivation of EBV
following a single infusion of TCZ [16].
It remains controversial whether TCZ also affects viral
loads of hepatitis B virus (HBV) and hepatitis C virus
(HCV). However, patients with active HBV infection
should be excluded because hepatitis B infection is often
exacerbated by various immunosuppressants [17].
Past history of serious infusion reaction
Although severe or life-threatening infusion reactions fol-
lowing TCZ administration are rare, a few cases with acute
reaction have been reported [4–6, 21]. History of serious
infusion reaction against TCZ is a contraindication, in line
with the manufacturer’s recommendation.
Use of TCZ
The recommended dosage and administration route of TCZ
in Japan is 8 mg/kg given once monthly as an intravenous
infusion over 1 h. Drug-related infusion reactions were
reported in clinical trials, although most were mild [4–6,
21]. Simultaneous administration of MTX is not manda-
tory, since clinical trials conducted in Japan were per-
formed with monotherapy.
Because TCZ can suppress elevation of CRP and ESR, it
is inadequate to evaluate its effectiveness by clinical
scores. Rather, it is recommended that any such evaluation
should be based on tender joint and swollen joint counts, or
on calculated scores that do not rely on CRP or ESR, e.g.,
the clinical disease activity index (CDAI) [18]. In addition,
the efﬁcacy of TCZ should be evaluated after at least
3 months of treatment because stable responses to TCZ
were only accomplished after such period in the published
clinical trials [4, 5].
Cautions for the safe use of TCZ
Infections
Infections are the most common adverse events during
TCZ therapy, although serious outcomes are rare [4–6, 19–
22]. In addition, all infections improve by appropriate
treatment, and no prolongation of treatment due to infec-
tion has been documented. Since pneumonia is a particu-
larly common and serious infection in RA patients [23], the
JCR has developed a speciﬁc algorithm for the differential
diagnosis of pneumonia (Fig. 1).
No speciﬁc pathogens were detected in patients with
pneumonia or other infections related to TCZ treatment [4–
6, 19–22]. No increase in tuberculosis was observed with
TCZ treatment [4, 5, 20–22], compared with the anti-TNF
agents [24]. However, TCZ therapy may signiﬁcantly alter
the onset or clinical course of pneumonia. There are
anecdotal reports that patients presenting with minimal
clinical symptoms develop severe pneumonia with shock
within 1 day of the start of TCZ therapy [25]. Sufﬁcient
evidence indicates that TCZ can suppress the elevation of
CRP and fever even in infections. CRP and fever are not
suitable markers of early stages of infection. Suppression
of inﬂammatory responses might delay the early diagnosis
of infections, especially pneumonia, and both patients and
physicians should be aware of this effect during TCZ
therapy.
Epidemiological studies have identiﬁed the risk fac-
tors for infection in RA patients. These include advanced
age [23, 26], pulmonary comorbidities [23, 26], corti-
costeroid use [23, 26], and impaired daily activity [21].
Patients with these risk factors should be considered
more susceptible to infections during TCZ therapy, and
tapering or ceasing corticosteroid use is strongly rec-
ommended. Patients should also be vaccinated prior to or
even during TCZ treatment against inﬂuenza and pneu-
mococcus if over 65 years old. TCZ does not alter the
response to vaccination against inﬂuenza or pneumo-
coccus [27, 28].
Bowel perforation
Several cases of bowel perforation followed by peritonitis
were reported in the clinical trials of TCZ [29]. Although
this adverse event is extremely rare, it is more infrequent
with other biologics including anti-TNF agents [30, 31].
Postmarketing surveillance should explore whether this
adverse event is speciﬁc to TCZ. In this regard, serum IL-6
level was elevated speciﬁcally prior to intestinal perfora-
tion [32, 33], and it is possible that TCZ could mask the
early symptoms of diverticulitis and hamper healing by its
inhibitory effect on IL-6/IL-6R signaling.
354 Mod Rheumatol (2009) 19:351–357
123Elevation of serum lipid concentrations
In clinical trials, serum lipid levels are often elevated
during TCZ therapy [4–6, 19–22]. Serum total cholesterol
increased in 38% of patients on TCZ monotherapy in one
Japanese study [5] and in 23% of the patients given a
combination of TCZ and nonbiologic DMARDs in a
European study [22]. However, total cholesterol levels
stabilized in the upper normal range in most cases. Fur-
thermore, the atherogenic index was not altered in these
cases due to accompanying increases in high-density
lipoprotein [5, 22].
Cardiovascular complications were rarely reported dur-
ing TCZ clinical trials, although the observation periods
were relatively short [5, 22]. Statin therapy is recom-
mended when lipid levels increase above normal range.
These phenomena are probably due to suppression of
inﬂammation, which can also be observed under anti-TNF
treatment. Nevertheless, elevated serum lipids during TCZ
treatment should be monitored during postmarketing sur-
veillance since IL-6 signaling might also directly affect
lipid metabolism.
Transient neutropenia
Neutropenia has been reported with TCZ treatment [6, 19–
22]. Neutrophil counts below 1,000/mm
3 were recorded,
although not associated with infection. The transient nature
of these changes indicates that margination of neutrophils
from the circulation in the bone marrow might be respon-
sible [19].
Combination with other DMARDs
Since the clinical trials of TCZ in Japan were designed as
monotherapy treatment [5], this drug has been approved
only for use without concomitant DMARDs. Clinical trials
in Western countries have shown the efﬁcacy of TCZ
treatment when combined with conventional DMARDs,
particularly MTX. Elevated levels of hepatic transaminases
were detected more frequently in the TCZ groups in these
trials [19, 21], although their levels were less than threefold
the upper limits of normal in the majority of patients and
returned to normal with repeated treatment. No such ﬁnd-
ings were reported in Japanese trials [4, 19, 22]. Monitor-
ing of serum liver enzymes is recommended during TCZ
treatment, especially when the latter is combined with
MTX.
Infusion reactions
Similar to other biologic agents, TCZ can induce infusion
reactions during or after the treatment day, although most
reactions are mild and transient [4–6, 19–22]. Infusion
Fever, Cough, Dyspnea (low PaO2, SpO2)
Physical examination, chest X-ray, CT,
laboratory tests, discontinuation
of tocilizumab
Exudative shadow Interstitial shadow
Detection of bacteria 
including TB by smear 
and/or culture of sputum 
and blood
Check for Pneumocystis jirovecii in
induced sputum or BALF, by PCR, or 
measure blood (1→  3)-β-D-glucan (β-
DG), as a marker of PCP.
Check for mycoplasma, chlamydia, 
legionella in serum and urine
Pneumocystis pneumonia
(PCP)
Bacterial pneumonia
or TB
Atypical pneumonia other than 
PCP
Drug-induced pneumonia (e.g. MTX)
Rheumatic lung diseases
Negative with β-DG
and PCR,
Positive for other 
pathogens
All negative
Unsuccessful treatment 
with antibiotics, unknown 
causative pathogen(s)
Recommended interpretation by radiologist 
or pulmonologist
Suggestive by 
β-DG or PCR 
for PCP
Any positive
All negative
Fig. 1 Diagnostic algorithm of pneumonia during tocilizumab therapy
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123reactions were observed in 11 out of 157 patients in the
SAMURAI trial [5]. Sleepiness, headache, and increased
blood pressure were observed but they were transient in
nature. However, preparation for severe infusion reactions
is recommended in case of emergencies; airway mainte-
nance, oxygen inhalation, subcutaneous epinephrine, and
intravenous corticosteroids should be available at bedside.
Surgery
The effect of IL-6 on wound healing remains to be clariﬁed
[34], although it is possible that wound healing might
be delayed under TCZ therapy. Moreover, the signs and
symptoms of surgical-site infection might be masked in
patients treated with TCZ, as discussed above. CRP levels
were completely normalized in patients with stable serum
TCZ levels [35]. At present, it is advisable that surgery is
postponed in patients on TCZ treatment until reduction of
drug level in peripheral blood, i.e., deferment of surgery to
at least 14 days after the last infusion of the drug.
Pregnancy and lactation
There are no data available on the safety of TCZ in preg-
nancy and lactation. IL-6 was reported to reduce recurrent
abortion in an animal model [36], however the effect of
TCZ on embryonic and fetal development is unknown.
Therefore, it is currently not recommended to administer
TCZ to pregnant women.
Malignancy
It remains unclear whether blocking of IL-6 signaling
affects the progression of malignancy [37]. IL-6 induces
cachexia in cancer patients, but might also inhibit prolif-
eration of certain types of cancer cells [38]. Administration
of TCZ to patients with present or recent history of
malignancy or precancerous lesions should be avoided at
present, in line with recommendations for anti-TNF agents.
Summary
TCZ is a novel therapeutic option for RA patients who
exhibit inadequate response to nonbiologic or biologic
DMARDs. Treatment with this drug prevented structural
joint damage in Japanese clinical trials. However, the
safety proﬁle of TCZ is not yet deﬁned since the numbers
of patients involved in the clinical trials are insufﬁcient to
detect infrequent but potentially serious adverse effects.
Therefore, the JCR has developed tentative guidelines for
the proper use of TCZ, and postmarketing surveillance is
underway according to these preliminary guidelines.
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